Riboscience prepares to showcase Phase 1b clinical data for its lead ENPP1 inhibitor, RBS2418, at the ESMO 2026 medical congress, marking a key milestone for the company's immunotherapy pipeline.
Riboscience announced presentation of Phase 1b data for its lead ENPP1 inhibitor RBS2418 at ESMO 2026, a clinical milestone with no efficacy results disclosed.
Riboscience announced that it will present Phase 1b clinical data for its lead oral ENPP1 inhibitor, RBS2418, at the upcoming European Society for Medical Oncology (ESMO) 2026 congress. The presentation marks a significant development milestone for the Palo Alto-based biotechnology firm as it advances its pipeline of first-in-class immunotherapies.
The company will present Phase 1b clinical trial data for RBS2418, an oral ENPP1 inhibitor, at the ESMO 2026 congress.